Company: VERA
Filing Date: 2025-04-03
Form Type: DEF 14A
Source: 0001140361-25-012034
Chunk: 56

Company: Vera Therapeutics, Inc.
Filing Date: 2025-04-03
Form: DEF 14A
Chunk 56
---
 the relevant fiscal year, the TSR reflected in this column represents the cumulative TSR of our common stock at the end of each fiscal year. In each case, we assume an initial investment of $100 on December 31, 2022. |

| (5) | The dollar amounts reported represent the amount of Net Income (Loss) reflected in the Company’s audited financial statements for the applicable year. |

37

TABLE OF CONTENTS Required Disclosure of the Relationship Between CAP and Financial Performance Measures As required by Item 402(v) of Regulation S-K, we are providing the following graphs to illustrate the relationship between the pay and performance figures that are included in the pay versus performance tabular disclosure above. As noted above, CAP for purposes of the tabular disclosure and the following graphs was calculated in accordance with SEC rules and does not reflect the amount of compensation earned by or actually paid to our NEOs during the applicable years. CAP and Net Income (Loss) The graph below shows the relationship between the CAP to our PEO and the average CAP to our Non-PEO NEOs, on the one hand, to the Company’s Net Income (Loss) over the two years presented in the table, on the other. 38 TABLE OF CONTENTS CAP and Cumulative TSR The graph below shows the relationship between the CAP to our PEO and the average CAP to our Non-PEO NEOs, on the one hand, to the Company’s cumulative TSR over the two years presented in the table, on the other. All information provided above under the “Item 402(v) Pay Versus Performance” heading will not be deemed to be incorporated by reference into any filing of the Company under the Securities Act or the Exchange Act whether made before or after the date hereof and irrespective of any general incorporation language in any such filing, except to the extent the Company specifically incorporates such information by reference. 39

TABLE OF CONTENTS

Equity Compensation Plan Information The following table provides certain information as of December 31, 2024, with respect to all of our equity compensation plans in effect on that date.

| Plan Category                                                 |     |     Number of 
 Securities to 
            be 
   Issued upon 
   Exercise of 
   Outstanding 
      Options, 
      Warrants 
    and Rights |     | Weighted-   
 average     
 Exercise    
 Price of    
 Outstanding 
 Options,    
 Warrants    
 and Rights  |     |        Number of 
       Securities 
        Remaining 
    Available for 
  Future Issu